Education
About Us
Working with TipRanks
Follow Us
PomDoctor Ltd. Unsponsored ADR (POM)
NASDAQ:POM
POM Stock Chart & Stats
$0.31
--
Market closed
$0.31
--
Day’s Range― - ―
52-Week Range$0.19 - $6.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.20M
Market Cap
$32.10M
Enterprise Value$631.64M
Total Cash (Recent Filing)$2.11B
Total Debt (Recent Filing)$37.66B
Price to Earnings (P/E)―
Beta1.47
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding106,192,310
10 Day Avg. Volume781,994
30 Day Avg. Volume2,198,746
Financial Highlights & Ratios
PEG Ratio14.95
Price to Book (P/B)-1.54
Price to Sales (P/S)10.17
P/FCF Ratio-215.48
Enterprise Value/Market Cap19.68
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit0.02
Enterprise Value/Ebitda0.08
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Insurance Integration / Reimbursement AccessEmbedding national and local insurance payment into its app/WeChat mini-program creates durable reimbursement access, improving patient affordability and retention. This structural integration raises barriers to entry, increases platform stickiness, and supports scalable, reimbursable chronic-care volumes over time.
Pharma Partnerships / Supply AdvantagesDirect partnerships with domestic pharma secure access to patented drugs, favorable purchase terms and rebates, and reduce reliance on intermediaries. That strengthens pricing and supply reliability, improves margins potential, and supports differentiated product breadth and distribution as the online hospital channel scales sustainably.
Revenue Growth And Capital SupportSustained top-line growth, driven by an 83% surge in online pharmacy, indicates strong product-market fit in digital drug distribution. Combined with fresh IPO capital, the company has runway to invest in technology, partnerships and geographic expansion, supporting continued structural revenue expansion over the medium term.
Bears Say
Negative Equity / Weak Balance SheetNegative shareholders' equity and liabilities above assets signal deep solvency risk and constrained financial flexibility. Over the medium term this raises refinancing risk, limits ability to fund R&D or M&A internally, and can force dilutive financing or asset sales to stabilize the balance sheet.
Persistent Unprofitability And Thin Gross MarginWide negative net margins and low gross margins show the company struggles to convert sales into sustainable profits. In healthcare, low gross margin reduces room for R&D and commercialization spend; without margin improvement, long-term viability depends on structural cost or pricing shifts that are not yet evident.
Negative Operating Cash Flow / Cash Conversion IssuesDespite FCF improvement, persistent negative operating cash flow and poor OCF-to-income conversion indicate operational cash burn. This undermines internal funding of growth, increases dependence on external capital, and elevates execution risk if capital markets tighten or additional financing becomes costly.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $0.19 and its highest was $6.43 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $32.10M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 106,192,310 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.